Vinorelbine injection

DRUG3 trials

Sponsors

Eisai Co., Ltd., Gilead Sciences, Henan Cancer Hospital

Conditions

Breast CancerBreast TumorsCancer of BreastHER2-Negative Breast CancerMetastatic Breast CancerTriple Negative Breast Cancer

Phase 2

Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer

Henan Cancer HospitalBreast Cancer

Start: 2022-03-22End: 2024-12-01Target: 134Updated: 2023-09-25

Phase 3

Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

CompletedNCT02225470

Eisai Co., Ltd.Breast Cancer, Breast Tumors, Cancer of Breast +2

Start: 2013-09-26End: 2018-06-22Updated: 2018-08-28

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

Active, not recruitingNCT04639986

Gilead SciencesMetastatic Breast Cancer

Start: 2020-11-23End: 2026-12-01Updated: 2026-02-09

Related Papers

Sacituzumab govitecan in HR<sup>+</sup>HER2<sup>-</sup> metastatic breast cancer: the randomized phase 3 EVER-132-002 trial.

2024-10-0125 citations

Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors.

2024-04-0517 citations

Incidence of peripheral neuropathy associated with eribulin mesylate versus vinorelbine in patients with metastatic breast cancer: sub-group analysis of a randomized phase III study.

2019-12-128 citations

Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial.

2019-03-2963 citations